<DOC>
	<DOCNO>NCT01286272</DOCNO>
	<brief_summary>This randomized phase II trial study well ofatumumab bendamustine hydrochloride without bortezomib work treat patient untreated follicular non-Hodgkin lymphoma . Monoclonal antibody , ofatumumab , may block cancer growth different way target certain cell . Drugs use chemotherapy , bendamustine hydrochloride , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Bortezomib may stop growth cancer cell block enzymes need cell growth . Bortezomib may also stop growth cancer cell block blood flow tumor . It yet know whether ofatumumab bendamustine hydrochloride effective bortezomib treat patient follicular non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Ofatumumab Bendamustine Hydrochloride With Without Bortezomib Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine complete response ( CR ) rate newly diagnose , untreated follicular lymphoma patient receive 6 cycle ofatumumab-bendamustine ( bendamustine hydrochloride ) ( ARM A ) 6 cycle ofatumumab , bortezomib , bendamustine ( ARM B ) use International Harmonization Project Response Criteria . SECONDARY OBJECTIVES : I . To determine progression-free survival ( PFS ) patient untreated follicular lymphoma 6 cycle ofatumumab-bendamustine ( ARM A ) follow maintenance ofatumumab 6 cycle ofatumumab , bortezomib , bendamustine follow maintenance ofatumumab bortezomib ( ARM B ) . II . To determine toxicity profile ofatumumab bendamustine ofatumumab , bortezomib , bendamustine patient untreated high-risk follicular lymphoma . III . To determine change qualitative semi-quantitative fludeoxyglucose ( FDG ) -positron-emission tomography ( PET ) finding baseline , cycle 2 ( day 32-35 ) , end therapy ( 6-8 week last cycle induction chemotherapy prior maintenance therapy ) ofatumumab-bendamustine ofatumumab , bortezomib , bendamustine correlate response PFS patient high-risk follicular lymphoma . IV . To assess combinatorial approach use qualitative semi-quantitative change FDG-PET compute tomography ( CT ) magnetic resonance imaging ( MRI ) study baseline , cycle 2 ( day 32-35 ) , end therapy ( 6-8 week last cycle induction chemotherapy prior maintenance therapy ) would result high predictive value response PFS patient high-risk follicular lymphoma . V. To correlate molecular parameter FDG-PET parameter determination response PFS . VI . To correlate pre-treatment single nucleotide polymorphism response PFS follow ofatumumab-bendamustine ofatumumab , bortezomib , bendamustine therapy patient untreated high-risk follicular lymphoma . VII . To correlate cluster differentiation ( CD ) -68 , B-cell chronic lymphocytic leukemia ( CLL ) /lymphoma ( bcl ) -2 , marker proliferation Ki-67 ( Ki-67 ) , forkhead box P3 ( FOXP3 ) , activate cytotoxic T-cells , lymphoma-associated macrophage ( LAM ) , melanoma associate antigen ( mutate ) 1 ( MUM1 ) , CD10 , nuclear v-rel avian reticuloendotheliosis viral oncogene homolog A ( p65 ) v-rel avian reticuloendotheliosis viral oncogene homolog C ( cREL ) subunits nuclear factor kappa light polypeptide gene enhancer B-cells ( NFkB ) , select genetic translocation fluorescent situ hybridization ( FISH ) analysis ( Bcl-2 Bcl-6 ) response PFS patient receive initial therapy high-risk follicular lymphoma . VIII . To determine whether immune gene signatures previously identify prognostic factor follicular lymphoma apply paraffin-embedded tissue ofatumumab bendamustine ofatumumab , bendamustine , bortezomib treat patient ; evaluate micro-ribonucleic acid ( RNA ) signatures associate gene signatures outcome . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : INDUCTION : Patients receive ofatumumab intravenously ( IV ) 2-8 hour day 1 bendamustine hydrochloride IV 30-60 minute day 1 2 . Treatment repeat every 35 day 6 course . Patients without disease progression continue maintenance therapy . MAINTENANCE : Beginning 8 week start induction course 6 , patient receive ofatumumab IV 2-8 hour day 1 . Treatment repeat every 56 day 4 course . ARM B : INDUCTION : Patients receive ofatumumab IV 2-8 hour day 1 , bendamustine hydrochloride IV 30-60 minute day 1 2 , bortezomib IV 3-5 second subcutaneously ( SC ) day 1 , 8 , 15 , 22 . Treatment repeat every 35 day 6 course . Patients without disease progression continue maintenance therapy . MAINTENANCE : Beginning 8 week start induction course 6 , patient receive ofatumumab IV 2-8 hour day 1 bortezomib IV 3-5 second SC day 1 , 8 , 15 , 22 . Treatment repeat every 56 day 4 course . After completion study treatment , patient follow every 4 month 2 year every 6 month 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm follicular nonHodgkin lymphoma , World Health Organization ( WHO ) classification grade 1 , 2 , 3a ( &gt; 15 centroblasts per highpower field centrocytes present ) Bone marrow biopsy sole mean diagnosis acceptable , may submit conjunction nodal biopsy Fineneedle aspirate acceptable Failure submit pathology within 60 day patient registration consider major protocol violation Patients must least one follow indicator poor risk disease : &gt; = 3 risk factor Follicular Lymphoma International Prognostic Index , 2 risk factor Follicular Lymphoma International Prognostic Index least one bulky mass lymph node &gt; 6 cm size Follicular Lymphoma International Prognostic Index ( FLIPI score ) : Age &gt; 60 year Involvement &gt; 4 nodal site Stage IIIIV disease Hemoglobin &lt; 12.0 g/dL Lactate dehydrogenase ( LDH ) &gt; upper limit normal ( ULN ) 01 risk factor : low risk 2 risk factor : intermediate risk &gt; = 3 risk factor : poor risk No prior cytotoxic chemotherapy , radiotherapy , immunotherapy , radioimmunotherapy No corticosteroid permit , except maintenance therapy nonmalignant disease prevent treatmentrelated ofatumumab reaction ( maintenance therapy dose must exceed 20 mg/day prednisone equivalent ) Measurable disease must present either physical examination image study ; nonmeasurable disease alone acceptable ; tumor mass &gt; 1 cm acceptable ; lesion consider nonmeasurable include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Bone marrow involvement ( involvement nonHodgkin lymphoma note ) Patients must know central nervous system ( CNS ) involvement lymphoma Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Patients must nonpregnant nonnursing ; pregnant nursing patient may enrol ; woman childbearing potential must negative serum urine pregnancy test within 14 day prior registration ; addition , woman men childbearing potential must commit use effective form contraception throughout participation study ; appropriate method birth control include abstinence , oral contraceptive , implantable hormonal contraceptive ( Norplant ) , double barrier method ( diaphragm plus condom ) Patients human immunodeficiency virus ( HIV ) infection eligible ; patient HIV infection must meet following : evidence coinfection hepatitis B C ; CD4+ count &gt; 400/ul ; evidence resistant strain HIV ; antiHIV therapy HIV viral load &lt; 50 copy HIV RNA/mL ; history acquire immunodeficiency syndrome ( AIDS ) define condition ; zidovudine stavudine allow owe overlap toxicity chemotherapy Patients must evidence active hepatitis B C infection ( i.e. , positive serology antihepatitis B core [ HBc ] antihepatitis C virus [ HCV ] antibody ) ; hepatitis B virus ( HBV ) seropositive patient ( hepatitis B surface antigen [ HBsAg ] + ) eligible HBV deoxyribonucleic acid ( DNA ) undetectable baseline closely monitor evidence active HBV infection HBV DNA test treatment cycle ; complete treatment , HBsAg + patient must monitor HBV DNA test every 2 month 6 month posttreatment , continue lamivudine Granulocytes &gt; = 1,000/uL Platelet count &gt; = 75,000/uL Creatinine = &lt; 2.0 mg/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x upper limit normal ( ULN ) Bilirubin = &lt; 2 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>